# A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Source: https://onco.cc/trials/nct06157827/  
OnCo record `nct06157827` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Opamtistomig run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.

## Summary

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma is a phase 1/2 interventional study registered as NCT06157827 by Nanjing Leads Biolabs Co.,Ltd, with 178 participants planned, started 2023-12-08. Conditions recorded: Advanced Neuroendocrine Carcinoma. Interventions recorded: LBL-024 for Injection, Etoposide Injection, Carboplatin Injection, Atezolizumab injection and Cisplatin injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06157827
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of LBL-024 Combined With Etoposide and Platinum in the First-line Treatment of Patients With Advanced Neuroendocrine Carcinoma (NEC)
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 178

## Sources

- ClinicalTrials.gov NCT06157827: https://clinicaltrials.gov/study/NCT06157827

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- drugs: [Opamtistomig](https://onco.cc/drugs/opamtistomig/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct06157827.json